Sweet Clover - Rylaze (Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn) Interaction
Herbal: Sweet Clover
Also Known As: Melilotus officinalis, Angipars, Casse Lunettes, Common Melilot, Couronne Royale, Field Melilot, Hart's Tree, Hay Flower, Herbe aux Puces, King's Clover, Luzerne Bâtarde, Melilot, Mélilot, Mélilot des Champs, Mélilot Commun, Mélilot Jaune, Mélilot Officinal
Drug: Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn
Brand names:
Rylaze

Medical Content Editor Dr. Brian Staiger, PharmD
Last updated
May 18, 2025
Interaction Details
Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn is classified as belonging to the following category: Hepatotoxic Drugs
Theoretically, concomitant use of sweet clover with hepatoxic drugs might increase the risk of hepatotoxicity.
Orally, large amounts of sweet clover can cause transient liver injury in susceptible individuals, possibly due to coumarin content. In one case report, a patient with multiple sclerosis developed jaundiced palms and a slight elevation in serum alanine aminotransferase (ALT) after taking sweet clover containing coumarin 10 mg daily for 3 years. Two weeks after starting therapy with subcutaneous interferon (IFN)-beta 1b, aspartate transaminase (AST) and ALT levels increased to 7 and 17 times the upper limit of normal, respectively. Levels normalized after discontinuation of both products. Subsequent use of IFN-beta 1a alone, without sweet clover, resulted in only a very slight increase in AST.
Interaction Rating
Likelihood of Occurrence
PossibleInteraction has been documented in animal or in lab research, or the interaction has been documented in humans but is limited to case reports or conflicting clinical research exists
References
- Gruenwald J, Brendler T, Jaenicke C. PDR for Herbal Medicines. 1st ed. Montvale, NJ: Medical Economics Company, Inc., 1998.
- Tamura S, Warabi Y, Matsubara S. Severe liver dysfunction possibly caused by the combination of interferon beta-1b therapy and melilot (sweet clover) supplement. J Clin Pharm Ther 2012;37(6):724-5.
Sweet Clover Overview

Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn Overview
-
Asparaginase erwinia chrysanthemi (recombinant)-rywn injection is used with other chemotherapy medications to treat acute lymphocytic leukemia (ALL; a type of cancer of the white blood cells) and to treat a type of non-Hodgkins lymphoma (NHL: cancer that begins in a type of white blood cell that normally fights infection) in adults and children 1 month of age and older. It is used in people who have had some types of allergic reactions to medications similar to asparaginase erwinia chrysanthemi (recombinant)-rywn such as asparaginase (Elspar). Asparaginase erwinia chrysanthemi (recombinant)-rywn is an enzyme that interferes with natural substances necessary for cancer cell growth. It works by killing or stopping the growth of cancer cells.
Sweet Clover - More Interactions
Sweet Clover interacts with 453 drugs
Interaction Rating Key
These severity listings are for informational use only. Never start, stop or otherwise change your therapy before speaking with your provider.
Major | The combined use of these agents is strongly discouraged as serious side effects or other negative outcomes could occur. |
Moderate | Use cautiously under the care of a healthcare professional or avoid this combination. A significant interaction or negative outcome could occur. |
Minor | Be aware that there is a chance of an interaction. Watch for warning signs of a potential interaction. |
Unknown | No interactions have been reported or no interaction data is currently available. |
Return to the main supplement interaction checker page
Parts of this content are provided by the Therapeutic Research Center, LLC.
DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.
© 2021 Therapeutic Research Center, LLC
Drug descriptions are provided by MedlinePlus.